Analyst Reco. Mirum Pharmaceuticals, Inc.

Equities

MIRM

US6047491013

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
24.42 ^USD	+1.03%		+2.39%	-17.28%

Apr. 17	Stifel Initiates Mirum Pharmaceuticals With Buy Rating, $48 Price Target	MT
Apr. 02	Mirum Pharmaceuticals, Inc. receives Positive Reimbursement Recommendation for Livmarli (Maralixibat Oral Solution) by Canada?S Cadth for Patients with Cholestatic Pruritus in Alagille Syndrome	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Stifel Initiates Mirum Pharmaceuticals With Buy Rating, $48 Price Target	Apr. 17	MT
JMP Securities Raises Price Target on Mirum Pharmaceuticals to $72 From $69, Maintains Market Outperform Rating	Mar. 14	MT
HC Wainwright Adjusts Mirum Pharmaceuticals Price Target to $58 From $45, Maintain Buy Rating	Mar. 14	MT
Cantor Fitzgerald Adjusts Price Target on Mirum Pharmaceuticals to $40 From $35, Maintains Overweight Rating	Mar. 04	MT
Raymond James Cuts Price Target on Mirum Pharmaceuticals to $64 From $78, Keeps Strong Buy Rating	Dec. 19	MT
Morgan Stanley Starts Mirum Pharmaceuticals With Overweight Rating, $60 Price Target	Nov. 13	MT
Cantor Fitzgerald Initiates Mirum Pharmaceuticals With Overweight Rating, Price Target is $50	23-10-24	MT
Raymond James Cuts Price Target on Mirum Pharmaceuticals to $77 From $84, Maintains Strong Buy Rating	23-10-18	MT
JMP Securities Initiates Mirum Pharmaceuticals With Market Outperform Rating, Price Target is $70	23-09-20	MT
Raymond James Raises Mirum Pharmaceuticals Price Target to $84 From $79, Maintains Strong Buy Rating	23-08-21	MT
Raymond James Adjusts Price Target on Mirum Pharmaceuticals to $79 From $82, Maintains Strong Buy Rating	23-08-04	MT
HC Wainwright Adjusts Mirum Pharmaceuticals Price Target to $63 From $61, Maintains Buy Rating	23-07-18	MT
Raymond James Adjusts Price Target on Mirum Pharmaceuticals to $82 From $81, Maintains Strong Buy Rating	23-07-18	MT
Raymond James Trims Price Target on Mirum Pharmaceuticals to $81 From $83, Maintains Strong Buy Rating	23-04-13	MT
Raymond James Adjusts Price Target on Mirum Pharmaceuticals to $83 From $84, Keeps Strong Buy Rating	23-03-09	MT
HC Wainwright Adjusts Mirum Pharmaceuticals Price Target to $61 From $69, Maintains Buy Rating	23-02-15	MT
Raymond James Adjusts Price Target on Mirum Pharmaceuticals to $84 From $88, Maintains Strong Buy Rating	23-01-10	MT
SVB Securities Adjusts Price Target on Mirum Pharmaceuticals to $39 From $50, Maintains Outperform Rating	23-01-10	MT
SVB Securities Adjusts Price Target on Mirum Pharmaceuticals to $50 From $49, Maintains Outperform Rating	22-12-14	MT
Citigroup Adjusts Price Target on Mirum Pharmaceuticals to $34 From $38, Maintains Buy Rating	22-11-10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Mirum Pharmaceuticals, Inc.

Equities

MIRM

US6047491013

Analyst Reco.

Filters